Trial Profile
A phase I/II study of INM-088 for the treatment of glaucoma
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Cannabinol (Primary) ; Cannabinol (Primary)
- Indications Glaucoma
- Focus Adverse reactions
- Sponsors InMed Pharmaceuticals
- 10 Jan 2023 According to an InMed Pharmaceuticals media release, several additional prospective patients have been identified for screening at the clinical sites; therefore, the Company decided to extend the enrollment period to the end of March 2023.
- 10 Jan 2023 According to an InMed Pharmaceuticals media release, company has completed a pre-Investigational New Drug application meeting with the FDA and gained alignment on the proposed design for this trial.
- 23 Sep 2022 According to an InMed Pharmaceuticals media release, the company expects to file regulatory applications in the first half of the calendar year 2024.